Brigham Research Institute Poster Session Site logo-1
Close this search box.

Manisha Bahl, MD, MPH




Associate Professor




Breast Imaging Radiologist




Sarah Mercaldo, Kimberlee Hashiba, Sheila Venkatesh, Tawakalitu Oseni, Manisha Bahl

Ductal carcinoma in situ presenting as screen-detected calcifications: patient, imaging, and pathological features associated with surgical upstaging

I am a breast imaging radiologist and NIH-funded investigator at MGH. My research is focused on supporting more targeted and precise treatment options for women with ductal carcinoma in situ (DCIS, or stage 0 breast cancer) and decreasing the morbidity and costs associated with overtreatment through the use of artificial intelligence and other innovative methodologies. I am proud to share this abstract prepared by my research team, all of whom are women in medicine and science. I believe that it’s important to participate in the Women in Medicine & Science Symposium to celebrate the achievements of women across different disciplines.


Several trials are underway to evaluate the safety and efficacy of active surveillance (AS) for women with ductal carcinoma in situ (DCIS). The purpose of this study is to identify patient, imaging, and pathological features associated with surgical upstaging of DCIS to invasive disease, in order to inform eligibility criteria for AS trials.


Medical records were retrospectively reviewed of women with screen-detected calcifications who were diagnosed with DCIS from 2007-16. Multiply imputed multivariable logistic regression models were fit to assess features associated with risk of upstaging to (1) any invasive disease (microinvasive disease [≤1 mm of invasive disease] or non-microinvasive disease) or (2) non-microinvasive disease only.


The upstaging rate of DCIS to invasive disease was 16% (161/1029). Of 161 upgrades, 35% (n=57) were upstaged to microinvasive disease and 65% (n=104) to non-microinvasive disease. Features associated with upstaging to any invasive disease were menopause above the age of 50, breast MR imaging, and intermediate or high nuclear grade of DCIS at biopsy (all p<0.05) The only feature associated with upstaging to non-microinvasive disease was MR imaging (p=0.004).


Identification of features associated with upstaging risk could be used to exclude certain women with high-risk DCIS from AS trials.